Novartis AG Stock News

In the most recent trading session, Novartis (NVS) closed at $106.31, indicating a +0.7% shift from the previous trading day.

Investors interested in Large Cap Pharmaceuticals stocks are likely familiar with Novartis (NVS) and Eli Lilly (LLY). But which of these two stocks presents investors with the better value opportunity

MAPS Public Benefit Corp. said Friday it raised $100 million in an oversubscribed Series A round of financing as it works to win approval from the U.S. Food and Drug Administration to become the first

Voyager Therapeutics' announcement that it has entered into an additional up to $1.2 billion collaboration with Novartis AG (ADR) (NYSE:NVS) for its TRACER capsids to develop potential gene therapies

Shares of Voyager Therapeutics Inc. (VYGR) jumped Tuesday after the biotech firm agreed to a strategic collaboration and capsid licensing agreement with Novartis AG (NVS) to treat neurological illness

Voyager Therapeutics Inc (NASDAQ:VYGR) shares rallied more than 30% in Tuesday pre-market trading after the company announced a strategic collaboration and capsid license agreement worth up to $1.2 bi

I review the stocks of five world-class companies that I am convinced will bring me closer to my ambitious goal of being able to fund my living expenses through dividends.

Big drug companies want to use artificial intelligence for a handful of purposes. Finding leads to make medicines more efficiently is one in-demand application.

In the most recent trading session, Novartis (NVS) closed at $98.87, indicating a -0.84% shift from the previous trading day.

This biotech giant remains a top stock for investors to buy and pays a solid 3.13% dividend.

Chimeric antigen receptor T-cell medicines could have more risks than previously known. Novartis' drug Kymriah is going to be under the most scrutiny for now.

Stocks are having their best November in 43 years, and stocks are now 13% historically overvalued. But thankfully, smart investors can always find incredible Warren Buffett-style bargains, both of the

The FDA has undertaken an investigation of T-cell malignancies in patients undergoing CAR T-cell therapy treatment. Therapies from NVS, BMY and GILD are under the spotlight.

With their robustness and growth potential, healthcare stocks are becoming a focal point in portfolios worldwide. Moreover, the U.S. stands out at the forefront of healthcare spending, allocating a st

Novartis (NVS) increases its sales guidance for the mid-term (2022-2027) and outlines its growth strategy as a pure-play pharmaceutical company.